SCHEMBL459946

SCHEMBL459946

CCOC(=O)c1ccc(F)c(OCc2c(C)cccc2C)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B2 P37059 1/20 0.47
SLC22A12 Q96S37 1/20 0.45
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44
CA7 P43166 2/20 0.44
CA9 Q16790 2/20 0.44
CA14 Q9ULX7 2/20 0.44
ESR1 P03372 1/20 0.44
ESR2 Q92731 1/20 0.44
RAB9A P51151 3/20 0.43
POLB P06746 1/20 0.43
PKM P14618 1/20 0.43
TTR P02766 1/20 0.42
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
TDP1 Q9NUW8 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL458612 0.88 SLC22A12 (0.58) HSD17B2SLC22A12CA12CA1CA2
SCHEMBL459191 0.85 MRGPRX4 (0.55) SLC22A12TTR
SCHEMBL31215374 0.85 MRGPRX4 (0.55) SLC22A12TTR
SCHEMBL460237 0.85 HSD17B2 (0.57) HSD17B2SLC22A12RAB9AHDAC1HDAC8
SCHEMBL15657613 0.83 HSD17B2 (0.56) HSD17B2CA12CA1CA2CA7
SCHEMBL458099 0.81 ALDH1A1 (0.51) HSD17B2SLC22A12RAB9APOLBPKM
SCHEMBL1634331 0.79 TDP1 (0.52) RAB9APOLBPKMTDP1L3MBTL1
SCHEMBL13568832 0.78 SLC22A12 (0.51) SLC22A12RAB9AL3MBTL1MEN1MAPT
SCHEMBL1340275 0.76 HSD17B2 (0.52) HSD17B2CA12CA1CA2CA7
SCHEMBL2175971 0.76 CA12 (0.59) HSD17B2CA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3517109-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2019-07-31 EP disclosed
EP-2268141-B1 COMPOUND AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORP (US) 2019-05-08 EP disclosed
US-10085957-B2 Benzoic acid compounds for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2018-10-02 US disclosed
US-20170042844-A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID PHARMA CINQ, LLC 2017-02-16 US disclosed
US-9115072-B2 Compounds and method for reducing uric acid WELLSTAT THERAPEUTICS CORPORATION (US) 2015-08-25 US disclosed
US-20130331452-A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-12-12 US disclosed
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2013-10-03 US disclosed
WO-2012033720-A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2012-03-15 WO disclosed
EP-2268141-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID Wellstat Therapeutics Corporation (US) 2011-01-05 EP disclosed
WO-2009151695-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID WELLSTAT THERAPEUTICS CORPORATION (US) 2009-12-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10085957-B2 Benzoic acid compounds for reducing uric acid FPR1, FFAR1, GLS HSD17B2 2561/4885SLC22A12 740/4885CA12 3091/4885
US-20130331452-A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID GLS, NLRP3, XDH HSD17B2 2954/4885SLC22A12 809/4885CA12 3875/4885
US-20130259850-A1 COMPOUNDS AND METHOD FOR REDUCING URIC ACID RCC2, HAX1, SLC10A6 HSD17B2 850/4885SLC22A12 139/4885CA12 1011/4885
US-20170042844-A1 BENZOIC ACID COMPOUNDS FOR REDUCING URIC ACID FPR1, FFAR1, GLS HSD17B2 2561/4885SLC22A12 740/4885CA12 3091/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.